SAN FRANCISCO, CA--(Marketwired - Aug 5, 2013) - Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in an interview with George Mack of The Life Sciences Report, "Cynapsus Therapeutics Inc. (
"I think it could be a $500M or more opportunity. Parkinson's is an enormous indication, and almost all Parkinson's patients experience this on/off phenomenon. This is a very clean, low-risk story, and I love the way Cynapsus has pulled this off, being the first to patent this delivery. If this were a U.S. stock, it would be four or five times the price it is now, but because it's in Canada, no one knows about it."
Continue reading this interview with Jason Napodano, "Off to the Races with Seven Extraordinary Biotech and Medtech Companies."
To Read Jason Napodano's comments on other companies, visit The Life Sciences Report.
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide valuable insights, integrated with in-depth company information, summaries from the latest research, and news that will help you make smart investment decisions.
Contact Information:
Contact Us
Streetwise Reports, LLC - The Life Sciences Report
Brandon Fung
Email:
Tel: 707-981-8107